Cargando…

The Role of the Immune System in Huntington's Disease

Huntington's disease (HD) is characterized by a progressive course of disease until death 15–20 years after the first symptoms occur and is caused by a mutation with expanded CAG repeats in the huntingtin (htt) protein. Mutant htt (mhtt) in the striatum is assumed to be the main reason for neur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ellrichmann, Gisa, Reick, Christiane, Saft, Carsten, Linker, Ralf A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3727178/ https://www.ncbi.nlm.nih.gov/pubmed/23956761 http://dx.doi.org/10.1155/2013/541259

Ejemplares similares

Efficacy of Fumaric Acid Esters in the R6/2 and YAC128 Models of Huntington's Disease
por: Ellrichmann, Gisa, et al.
Publicado: (2011)

Positive effect of immunomodulatory therapies on disease progression in Huntington’s disease? Data from a real-world cohort
por: Achenbach, Jannis, et al.
Publicado: (2022)

Increase of angiotensin II type 1 receptor auto-antibodies in Huntington’s disease
por: Lee, De-Hyung, et al.
Publicado: (2014)

Laquinimod treatment in the R6/2 mouse model
por: Ellrichmann, Gisa, et al.
Publicado: (2017)

Author Correction: Laquinimod treatment in the R6/2 mouse model
por: Ellrichmann, Gisa, et al.
Publicado: (2019)

Error Processing in Huntington's Disease
por: Beste, Christian, et al.
Publicado: (2006)

Evidences for Mutant Huntingtin Inducing Musculoskeletal and Brain Growth Impairments via Disturbing Testosterone Biosynthesis in Male Huntington Disease Animals
por: Yu-Taeger, Libo, et al.
Publicado: (2022)

Constitutive activity of NF-kappa B in myeloid cells drives pathogenicity of monocytes and macrophages during autoimmune neuroinflammation
por: Ellrichmann, Gisa, et al.
Publicado: (2012)

Resurrection of sildenafil: potential for Huntington’s Disease, too?
por: Achenbach, Jannis, et al.
Publicado: (2022)

Time Processing in Huntington's Disease: A Group-Control Study
por: Beste, Christian, et al.
Publicado: (2007)

Music perception and movement deterioration in Huntington’s disease
por: Beste, Christian, et al.
Publicado: (2011)

Differential Diagnosis of Chorea—HIV Infection Delays Diagnosis of Huntington’s Disease by Years
por: Achenbach, Jannis, et al.
Publicado: (2021)

Phonatory Dysfunction as a Preclinical Symptom of Huntington Disease
por: Rusz, Jan, et al.
Publicado: (2014)

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience
por: Schneider-Gold, Christiane, et al.
Publicado: (2017)

Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits
por: Thöne, Jan, et al.
Publicado: (2013)

Oral and dental health in Huntington‘s disease - an observational study
por: Saft, Carsten, et al.
Publicado: (2013)

Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders
por: Ellrichmann, Gisa, et al.
Publicado: (2018)

Another Perspective on Huntington’s Disease: Disease Burden in Family Members and Pre-Manifest HD When Compared to Genotype-Negative Participants from ENROLL-HD
por: Achenbach, Jannis, et al.
Publicado: (2021)

PGC-1alpha as modifier of onset age in Huntington disease
por: Taherzadeh-Fard, Elahe, et al.
Publicado: (2009)

No evidence of impaired gastric emptying in early Huntington‘s Disease
por: Saft, Carsten, et al.
Publicado: (2011)

Longitudinal Evaluation of the Effect of Tricyclic Antidepressants and Neuroleptics on the Course of Huntington’s Disease—Data from a Real World Cohort
por: Achenbach, Jannis, et al.
Publicado: (2021)

Insight into Metabolic (1)H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain Lesions
por: Schneider, Ruth, et al.
Publicado: (2017)

A novel cognitive-neurophysiological state biomarker in premanifest Huntington's disease validated on longitudinal data
por: Beste, Christian, et al.
Publicado: (2013)

Does arterial hypertension influence the onset of Huntington's disease?
por: Valcárcel-Ocete, Leire, et al.
Publicado: (2018)

Glutathione S-Transferase Ω 1 variation does not influence age at onset of Huntington's disease
por: Arning, Larissa, et al.
Publicado: (2004)

Divergent Effects of the Nonselective Adenosine Receptor Antagonist Caffeine in Pre-Manifest and Motor-Manifest Huntington’s Disease
por: Achenbach, Jannis, et al.
Publicado: (2022)

Altered third‐party punishment in Huntington's disease: A study using neuroeconomic games
por: Brüne, Martin, et al.
Publicado: (2020)

No optical coherence tomography changes in premanifest Huntington's disease mutation carriers far from disease onset
por: Schmid, Rahel Dominique, et al.
Publicado: (2022)

Symptomatic treatment options for Huntington’s disease (guidelines of the German Neurological Society)
por: Saft, Carsten, et al.
Publicado: (2023)

Functional and cognitive capacity differ in dystonic motor subtypes when compared to choreatic and hypokinetic‐rigid motor subtypes in Huntington's disease
por: Achenbach, Jannis, et al.
Publicado: (2020)

No association between polymorphisms in the BDNF gene and age at onset in Huntington disease
por: Mai, Maren, et al.
Publicado: (2006)

Time will tell: Decision making in premanifest and manifest Huntington’s disease
por: Heim, Beatrice, et al.
Publicado: (2020)

Failure to confirm influence of Methyltetrahydrofolate reductase (MTHFR) polymorphisms on age at onset of Huntington disease
por: Hansen, Wiebke, et al.
Publicado: (2005)

Huntington's Disease: An Immune Perspective
por: Nayak, Annapurna, et al.
Publicado: (2011)

Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome in seven patients with sarcoidosis: a critical discussion of treatment and prognosis
por: Dohrn, Maike F., et al.
Publicado: (2021)

Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series
por: Saft, Carsten, et al.
Publicado: (2006)

Metabolic profiles by (1)H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML)
por: Schneider, Ruth, et al.
Publicado: (2017)

PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease
por: Taherzadeh-Fard, Elahe, et al.
Publicado: (2011)

Management of Huntington’s disease: role of tetrabenazine
por: de Tommaso, Marina, et al.
Publicado: (2011)

Emerging Roles of Exosomes in Huntington’s Disease
por: Ananbeh, Hanadi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e6u5m6tcjbu265350gcg89t1tf